{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5+mg+prednisone", "query": { "intervention": "5 mg prednisone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 427, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5+mg+prednisone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T00:59:59.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04002947", "title": "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Diffuse Large B-Cell Lymphoma", "DLBCL", "NHL" ], "interventions": [ { "name": "DA-EPOCH", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "CHOP", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2019-08-05", "completion_date": "2031-03-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04002947" }, { "nct_id": "NCT00873093", "title": "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "L-asparaginase", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "High Dose MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 148, "start_date": "2009-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873093" }, { "nct_id": "NCT01425099", "title": "Drug Interaction Study Between Dolutegravir and Prednisone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2011-09", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-11-07", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425099" }, { "nct_id": "NCT06315309", "title": "Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GVHD,Acute", "Acute Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Disorders" ], "interventions": [ { "name": "ATG Combined with Tacrolimus and Mini Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 29, "start_date": "2025-04-15", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06315309" }, { "nct_id": "NCT06329830", "title": "177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Castration-resistant Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "Niraparib abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2024-10", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06329830" }, { "nct_id": "NCT00882206", "title": "Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "decitabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "2 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2009-04", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882206" }, { "nct_id": "NCT04046549", "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allografts", "Rejection; Transplant, Kidney", "Transplant Rejection", "Kidney Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "VIB4920", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2019-10-30", "completion_date": "2023-03-22", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046549" }, { "nct_id": "NCT01688492", "title": "Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2012-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 3, "location_summary": "Evanston, Illinois • New York, New York • Portland, Oregon", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688492" }, { "nct_id": "NCT00003700", "title": "Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 163, "start_date": "1999-01", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 50, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003700" }, { "nct_id": "NCT05389423", "title": "Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large Cell Lymphoma", "Non-Hodgkin Lymphoma", "Burkitt Lymphoma", "Plasmablastic Lymphoma", "B-Cell Neoplasm" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2023-06-27", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-16T00:59:59.901Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05389423" } ] }